Leukocyte-specific phosphoprotein-1 and PU.1: Two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease

Haematologica

Volumn 89, Issue 8, 2004, Pages 957-964

  Marafioti, Teresa ^b   Mancini, Cristina ^a   Ascani, Stefano ^a   Sabattini, Elena ^a   Zinzani, Pier Luigi ^a   Pozzobon, Michela ^c   Pulford, Karen ^b   Falini, Brunangelo ^d   Jaffe, Elaine S ^e   Müller Hermelink, Hans Konrad ^f   Mason, David Y ^b   Pileri, Stefano A ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PERUGIA   (Italy)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Diagnosis; LSP1; Lymphocyte predominant Hodgkin's disease; Lymphocyte rich classical Hodgkin's disease; Phenotype; PU.1; T cell rich B cell lymphoma

Indexed keywords

LEUKOCYTE SPECIFIC PHOSPHOPROTEIN 1; PHOSPHOPROTEIN; PROTEIN ANTIBODY; REAGENT; TRANSCRIPTION FACTOR PU 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTIOCYTE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOCYTE PREDOMINANT HODGKIN DISEASE; LYMPHOCYTE RICH CLASSICAL HODGKIN DISEASE; MALE; PHENOTYPE; PROTEIN EXPRESSION; RARE DISEASE; T CELL RICH B CELL LYMPHOMA;

EID: 3943052628     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology 2002;40:31-45.
2. Chittal SM, Brousset P, Voigt JJ, Delsol G. Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease. Histopathology 1991;19:211-20.
3. Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992;16:37-48.
4. Fraga M, Sanchez-Verde L, Forteza J, Garcia-Rivero A, Piris MA. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology 2002;41:216-29.
5. Gatter K, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of the haematopoietic and lymphoid system. Lyon: IARC Press, 2001. p. 171-4.
6. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
7. Macon WR, Williams ME, Greer JP, Stein RS, Collins RD, Cousar JB. T-cell-rich B-cell lymphomas. A clinicopathologic study of 19 cases. Am J Surg Pathol 1992;16:351-63.
8. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988;12:433-43.
9. Rüdiger T, Jaffe ES, Delsol G, de Wolf-Peeters C, Gascoyne RD, Georgii A, et al. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Ann Oncol 1998;9Suppl 5:S31-8.
10. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889-99.
11. Ashton-Key M, Isaacson PG. CD45 immunostaining in T-cell-rich B-cell lymphoma and lymphocyte predominance Hodgkin's disease. J Pathol 1997;181:462-3.
12. De Jong D, Van Gorp J, Sie-Go D, Van Heerde P. T-cell rich B-cell non-Hodgkin's lymphoma: a progressed form of follicle centre cell lymphoma and lymphocyte predominance Hodgkin's disease. Histopathology 1996;28:15-24.
13. Rüdiger T, Gascoyne RD, Jaffe ES, de Jong D, Delabie J, De Wolf-Peeters C, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol 2002;13Suppl 1:44-51.
14. Bräuninger A, Küppers R, Spieker T, Spiekert T, Siebert R, Strikler JG, et al. Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumour cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. Blood 1999;93:2679-87.
15. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, Delsol G, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997;337:453-58.
16. Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997;337:459-65.
17. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-cell/histiocyte- rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002;20:1269-77.
18. + anaplastic B-cell subtypes exhibit distinct clinical features. Ann Oncol 2001;12: 853-8.
19. Ripp JA, Loiue DC, Chan W, Nawaz H, Portlock CS. T-cell rich B-cell lymphoma: clinical distinctiveness and response to treatment in 45 patients. Leuk Lymphoma 2002;43:1573-80.
20. Franke S, Wlodarska I, Maes B, Vandemberghe P, Achten R, Hagemeijer A, et al. Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol 2002;161:1861-7.
21. Peh SC, Kim LH, Poppema S. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 2001;25:925-9.
22. Lim MS, Beaty M, Sorbara L, Cheng RZ, Pittaluga S, Raffeld M, et al. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol 2002;26:1458-66.
23. Boudová L, Torlakovíc E, Delabie J, Reimer P, Pfistner B, Wiedenman S, et al. Nodular lymphocyte predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte rich B-cell lymphoma. Blood 2003;102:3753-8.
24. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001;159:1807-14.
25. Henderson A, Calame K. Transcriptional regulation during B cell development. Annu Rev Immunol 1998;16:163-200.
26. Lloberas J, Soler C, Celada A. The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages. Immunol Today 1999;20:184-9.
27. Marafioti T, Jabri L, Pulford K, Brousset P, Mason DY, Delsol G. Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin's disease. Br J Haematol 2003;120:671-8.
28. Stein H, Delsol G, Pileri S, Said J, Mann R, Poppema S, et al. Classical Hodgkin Lymphoma. In: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid System, Jaffe ES, Harris NL, Stein H, Vardiman JW eds. IARC Press: Lyon, 2001. p. 244-53.
29. Fan Z, Naktuman Y, Bair E, Tibshirami R, Warnke RA. Characterization of variants patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003;27:1346-56.
30. Falini B, Pileri S, Martelli MF. Histological and immunohistological analysis of human lymphomas. Crit Rev Oncol Hematol 1989;9:351-419.
31. Pileri SA, Roncador G, Ceccarelli C, Piccioli M, Sabattini E, Briskomatis, et al. Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol 1997;183:116-23.
32. Cordell JL, Falini B, Erber WN, Ghosh AK, Abduazziz Z, MacDonald S, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
33. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, et al. The EnVision++ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques. J Clin Pathol 1998;51:506-11.
34. Mason DY, Micklem K, Jones M. Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol 2000;191:452-61.
35. Jundt F, Kley K, Anagnostopoulos I, Schulze Probsting K, Greiner A, Mathas S, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002;99:3060-2.
36. Loddenkemper C, Anagnostopoulos I, Hummel M, Jöhrens-Leder K, Foss H-D, Jundt F, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct.2, PU.1 and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin's lymphomas, and Hodgkin's lymphomas. J Pathol 2004;202:60-9.
37. Jongstra-Bilen J, Misener VL, Wang C, Ginrberg H, Auerbach A, Joyner AL, et al. LSP1 modulates leukocyte populations in resting and inflamed peritoneum. Blood 2000;96:1827-35.
38. Li Y, Zhang Q, Aaron R, Hilliard L, Howard TH. LSP1 modulates the locomotion of monocyte-differentiated U937 cells. Blood 2000;96:1100-5.
39. Miyoshi EK, Stewart PL, Kincade PW, Lee MB, Thompson AA, Wall R. Aberrant expression and localization of the cytoskeleton-binding pp52 (LSP1) protein in hairy cell leukemia. Leuk Res 2001;25:57-67.
40. Wang C, Hayashi H, Harrison R, Chan JR, Ostergaard HL. Modulation of Mac-1 (CD11β/CD18)-mediated adhesion by the leukocyte-specific protein 1 is key to its role in neutrophil polarization and chemotaxis. J Immunol 2002;169:415-23.
41. Zhang Q, Li Y, Howard TH. Hair-forming activity of human lymphocyte specific protein 1 requires cooperation between its caldesmon-like domains and the villin headpiece-like domains. Cell Motil Cytoskeleton 2001;49:179-88.